- |||||||||| foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Journal: 3D Chromatin Alteration by Disrupting ?-Catenin/CBP Interaction Is Enriched with Insulin Signaling in Pancreatic Cancer. (Pubmed Central) - Jun 27, 2024
The therapeutic potential of targeting the ?-catenin/CBP interaction has been demonstrated in a variety of preclinical tumor models with a small molecule inhibitor, ICG-001, characterized as a ?-catenin/CBP antagonist...We finally elicit the deletion of a looping of IRS1-a key insulin signaling gene-significantly impeding pancreatic cancer cell growth, indicating that looping-mediated insulin signaling might act as an oncogenic pathway to promote pancreatic cancer progression. Our work shows that targeting aberrant insulin chromatin looping in pancreatic cancer might provide a therapeutic benefit.
|
